Search
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Products: SIGNIFOR® LAR 20 MG, SIGNIFOR® LAR 40 MGDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD). … [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe.
Products: Desvenlafaxine ER, STYMA 50 MGAzatadine
go.drugbank.com/drugs/DB00719ApprovedWithdrawnAntihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.
Products: Optimine Tab 1mgEpirubicin
go.drugbank.com/drugs/DB00445ApprovedInvestigationalAn anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Products: E.P.Mycin injection 2mg/ml, Eberubi Injection 2mg/mlHydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus … [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.
Products: Atarax Cap 10mg, Multipax Cap 10mgSomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. … [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666]
Products: SOGROYA® 10MG/1.5ML, SOGROYA® 5MG/1.5MLMinoxidil
go.drugbank.com/drugs/DB00350ApprovedInvestigationalA potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Categories: Arteriolar Smooth Muscle, Agents Acting OnProducts: TRIATOP®ESPUMA TÓPICA EN AEROSOL, TYLCORE® ESPUMA TÓPICA EN AEROSOLMoxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnIt is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.
Products: MOXONIDINA EG, Normohex 0,2 mg - FilmtablettenCimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalIt inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. … A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions.
Synonyms: N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine, N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidineProducts: Tagamet Infusion 6mg/ml, Cimetidine in Sodium ChlorideSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSINA EG, UROREC 4MG